Toll-Like Receptor

TLR4 — the molecular tripwire for Gram-negative sepsis

Imagine a single molecule of LPS, the outer-membrane glycolipid of E. coli, drifting through plasma. Here is what happens:

1. Plasma binding. Lipopolysaccharide-binding protein (LBP), an acute-phase protein, snatches the LPS and shuttles it to CD14 on the macrophage surface.
2. Loading MD2. CD14 transfers the lipid A moiety into the hydrophobic pocket of MD2, a small protein perched at the entrance of TLR4.
3. Dimerization. A second TLR4-MD2 complex, also occupied by a lipid A, joins it — forming an "M-shaped" dimer of dimers.
4. Intracellular signal. The TIR (Toll/IL-1 receptor) domains on the cytoplasmic tails come together. MyD88 binds; IRAK4 phosphorylates IRAK1; TRAF6 is ubiquitinated; TAK1 activates the IKK complex.
5. NF-κB liberation. IKK phosphorylates IκB; ubiquitin-tagged IκB is degraded; NF-κB heterodimers (p65/p50) translocate to the nucleus.
6. Cytokine storm. NF-κB binds promoters of TNF-α, IL-1β, IL-6, IL-12, and dozens of other inflammatory genes. Translation begins within minutes; protein appears within an hour.
7. Endosomal switch. Some TLR4 is internalized and now signals through TRIF → IRF3 → IFN-β, adding type I interferon to the cytokine output.

This is the molecular tripwire of Gram-negative sepsis. Picomolar LPS at a wound site is appropriate alarm. Nanomolar LPS in the bloodstream is septic shock — exquisite sensitivity become catastrophic.

Endosomal TLRs — viral nucleic acid sensors

The endosomal subgroup solves a hard problem: how to detect nucleic acid (a quintessentially intracellular molecule) without firing on host RNA and DNA. The answer is spatial: TLR3, 7, 8, 9 are trafficked by UNC93B1 from the ER to endolysosomes. They only encounter nucleic acid that has been engulfed from outside — a virion processed in an endosome, bacterial DNA from phagocytosed cells.

• TLR3 recognizes double-stranded RNA (viral replication intermediates). It uses TRIF, not MyD88, and signals strongly through IRF3 → IFN-β.
• TLR7 (in B cells, plasmacytoid DCs) detects single-stranded RNA (HIV, influenza, SARS-CoV-2). Imiquimod and resiquimod are synthetic TLR7 agonists.
• TLR8 (in myeloid DCs, monocytes) also detects ssRNA. Sex-biased — TLR7 and TLR8 are X-linked and contribute to sex differences in vaccine responses and autoimmunity.
• TLR9 detects unmethylated CpG dinucleotides — common in bacterial DNA, rare in mammalian. CpG oligonucleotides like CpG-1018 are vaccine adjuvants.

Worked clinical example: child with recurrent pneumococcal disease

A 4-year-old has had three episodes of invasive pneumococcal disease — bacteremia at 14 months, meningitis at 28 months, and now empyema at 4 years. Total immunoglobulins are normal. Complement is normal. Specific antibody response to vaccines is preserved. The immunology team suspects an innate signaling defect and orders whole-exome sequencing. He carries a homozygous loss-of-function variant in IRAK4. The diagnosis matches the clinical phenotype precisely: IRAK4 deficiency causes selective severe susceptibility to pyogenic bacteria (S. pneumoniae, S. aureus) because the MyD88-IRAK4 axis is the indispensable bottleneck for TLR signaling against bacterial PAMPs. Viral immunity (TLR3-TRIF, RIG-I, IFN) is preserved, so he has not had unusual viral disease. He is placed on daily penicillin prophylaxis, receives 23-valent pneumococcal polysaccharide booster, and the family is counseled that susceptibility tends to wane after the first decade — adaptive immunity slowly compensates. The diagnosis was molecular, the management is practical, and both flow from the architecture of TLR signaling.

Why TLRs matter clinically

• Sepsis. LPS-TLR4 signaling drives most Gram-negative septic shock; the mechanism of cytokine storm.
• Vaccine adjuvants. MPL (TLR4) in Shingrix and Cervarix; CpG-1018 (TLR9) in Heplisav-B; explains the superior efficacy of these formulations.
• Topical oncology and dermatology. Imiquimod (TLR7) for genital warts and superficial basal cell carcinoma; BCG (TLR2/4) for bladder cancer.
• Innate immunodeficiency. IRAK4 and MyD88 loss-of-function — severe pyogenic disease in childhood; UNC93B1/TLR3/TRIF defects — herpes simplex encephalitis.
• Lupus and Sjogren's. Endosomal TLR7/9 stimulation by self-nucleic acids drives the IFN signature; hydroxychloroquine partly works through endosomal TLR antagonism.
• Lymphoma genetics. MyD88 L265P somatic mutation activates chronic TLR signaling in Waldenström macroglobulinemia and ABC-DLBCL — sensitive to BTK inhibition.
• Cancer immunotherapy. Intratumoral TLR9 agonists combined with checkpoint inhibitors to convert cold tumors to hot.

TLR family at a glance

TLR	Location	Ligand (PAMP)	Main pathogen class
TLR2 / TLR1, TLR6	Surface	Lipopeptides, peptidoglycan	Gram-positive bacteria, mycobacteria
TLR3	Endosome	dsRNA	Viruses (replication intermediates)
TLR4 + MD2	Surface (+ endosome)	LPS, lipid A	Gram-negative bacteria
TLR5	Surface	Flagellin	Motile bacteria
TLR7 / TLR8	Endosome	ssRNA, imidazoquinolines	RNA viruses (HIV, influenza, SARS-CoV-2)
TLR9	Endosome	Unmethylated CpG DNA	Bacteria, DNA viruses

Common misconceptions

• TLRs are antigen-specific. They are pattern recognition — broad classes of molecules shared by many pathogens, not individual antigens.
• All TLRs are the same. Surface vs endosomal location, MyD88 vs TRIF adapter, and tissue distribution all differ; effects are not interchangeable.
• LPS detection is direct. Requires LBP, CD14, and MD2 as cofactors — TLR4 alone cannot bind lipid A.
• NF-κB is the only output. TLR3 and endocytosed TLR4 drive IFN-β through IRF3 — antiviral, not just inflammatory.
• Vaccine adjuvants are non-specific irritants. Modern adjuvants like MPL and CpG act through defined TLR engagement and shape the qualitative immune response.
• Blocking TLR4 cures sepsis. Multiple trials of TLR4 antagonists have failed — the cytokine cascade has redundant amplifiers downstream.